Clinical Scorecard: Evaluating the Completeness of Human Safety Assessments for Succinate Dehydrogenase Inhibitors: A Case Study of Fluopyram
At a Glance
Category
Detail
Condition
Potential toxic effects of succinate dehydrogenase inhibitor fungicides on human health
Key Mechanisms
Inhibition of succinate dehydrogenase (SDH), complex II of the mitochondrial electron transport chain
Target Population
Humans, including potentially sensitive subpopulations with genetic SDH defects or oxidative hypersensitivity
Care Setting
Regulatory toxicology and pesticide safety assessment
Key Highlights
SDH inhibitors like fluopyram target fungal pathogens but may also affect SDH in non-target species including humans.
Regulatory human safety studies for fluopyram include extensive mandated toxicity testing under Good Laboratory Practice (GLP) standards.
Current evidence and regulatory reviews do not support a human health alert from SDH inhibitor fungicides despite ongoing scientific discussion.
Guideline-Based Recommendations
Diagnosis
No direct diagnostic guidelines; focus is on comprehensive toxicological evaluation of SDH inhibitors.
Management
Conduct mandated human safety studies following internationally approved OECD test guidelines.
Use maximum tolerated dose (MTD) to set dose levels in toxicity studies.
Monitoring & Follow-up
Monitor multiple endpoints including general toxicity, neurological effects, and carcinogenicity over varied study durations.
Ensure studies comply with Good Laboratory Practice (GLP) and animal welfare regulations.
Risks
Potential risks include neurological, neurodegenerative diseases, and cancer hypothesized from SDH inhibition but not confirmed in regulatory assessments.
Consider possible increased sensitivity in subpopulations with genetic SDH defects or oxidative stress susceptibility.
Patient & Prescribing Data
General human population including potentially sensitive individuals with SDH-related vulnerabilities
Fluopyram is primarily a fungicide with no human therapeutic use; safety assessments indicate acceptable risk levels under regulatory standards.
Clinical Best Practices
Perform extensive, guideline-compliant toxicology studies including multiple dose groups and both sexes.
Use large sample sizes and long-term studies to detect both acute and chronic toxicities.
Maintain transparency by providing study summaries publicly and full reports upon request.
Critically evaluate potential SDH-related toxicities within the context of comprehensive data sets and regulatory reviews.
